Evolving strategies in the management of aspergillosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 193-209

  Magill, Shelley S ^a   Chiller, Tom M ^a   Warnock, David W ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Antifungal agents; Aspergillosis; Aspergillus; Hematopoietic stem cell transplantation; Mycoses; Solid organ transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FUNGUS VACCINE; GAMMA1B INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAPAMYCIN; RECOMBINANT GAMMA INTERFERON; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ADRENAL INSUFFICIENCY; ANAPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HALLUCINATION; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; IMMUNOTHERAPY; INFECTION CONTROL; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; LUNG EMBOLISM; MONOTHERAPY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PHOTOSENSITIVITY; QT PROLONGATION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SKIN MANIFESTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VACCINATION; VISUAL DISORDER; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY;

EID: 39049127822     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.193     Document Type: Review

References (165)

1. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002;4(4):195-200
2. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100(13):4358-66
3. Lin SSJ, Schranz JJ, Teutsch SSM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32(3):358-66
4. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(Suppl 1):S49-58
5. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44(4):531-40
6. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004;101(7):1594-600
7. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350(9):950-2
8. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004;39(4):584-7
9. Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005;41(1):60-6
10. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005;40(4):e35-7
11. Stevens DDA, Kan VVL, Judson MMA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):696-709
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15
13. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. BMJ (Clin Res Ed) 2001;322(7286):579-82
14. Hiemenz JW. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference? Clin Infect Dis 2003;36(8):952-3
15. Lewis RE, Wiederhold NP. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003;37(6):871-2
16. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006;50(10):3418-23
17. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000;182(1):274-82
18. Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007;51(4):1253-8
19. Wingard JR Jr. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002;35(7):891-5
20. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27(2):296-302
21. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35(4):359-66
22. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25(5):1295-320
23. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44(10):1289-97
24. Janssen Pharmaceutica Products, L.P. Sporanox (Itraconazole) Injection package insert. June 2006 [cited 2007 November 16]; Available from: http://www.orthobiotech.com/common/prescribing_information/SPORANOX/PDF/ Sporanox_Injection.pdf
25. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357(9270):1766-7
26. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005;56(Suppl 1):i33-8
27. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006;6:6
28. Vfend I.V. (voriconazole) for Injection; Vfend Tablets (voriconazole); Vfend: (voriconazole) for Oral Suspension package insert. November 2006 [cited 2007 November 16]; Available from: http://media.pfizer.com/files/ products/uspi_vfend.pdf
29. Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis 2004;39(8):1241-4
30. Agrawal AK, Sherman LK. Voriconazole-induced musical hallucinations. Infection 2004;32(5):293-5
31. McCarrhy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007;44(5):e55-6
32. Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol 2004;43(10):768-71
33. Alkan Y, Haefeli WE, Burbenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 2004;39(6):e49-52
34. Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007;9(1):33-6
35. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67(2):269-98
36. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration afrer allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(5):552-9
37. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004;36(9):2708-9
38. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71
39. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109(8):1532-5
40. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50(4):1570-2
41. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualization. Clin Infect Dis 2003;36(8): 1087-8
42. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46(2):235-43
43. Brown J, Freeman BB, Rethinking the use of voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;36(2):177.
44. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46(2):229-34
45. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51(7):2587-90
46. Noxafil (posaconazole) oral suspension package insert. October 2006 [cited 2007 November 16]; Available from: http://www.spfiles.com/ pinoxafil.pdf
47. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59
48. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
49. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12
50. Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004;42(3):1376-8
51. Baden LR, Marty FM. Posaconazole for invasive aspergillosis? Clin Infect Dis 2007;45(5):664, author reply 5-6
52. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42(12):1726-34
53. Center for Drug Evaluation and Research, Application Number 22-003, Clinical Pharmacology and Biopharmaceutics Review. 2005 [cited 2007 November 16]; Available from: http://www.fda.gov/cder/foi/nda/2006/ 022003s000_Noxafil_ClinPharmR.pdf
54. Kauffman CA, Malani AN, Easley C, Kirkpatrick P. Posaconazole. Nat Rev Drug Discov 2007;6(3):183-4
55. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42(7):e61-5
56. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002;34(12):1648-50
57. Weiler S, Bellmann R. Posaconazole prophylaxis in hematologic cancer. N Engl J Med 2007;356(21):2214, author reply 5-8
58. Kontoyiannis DP, Lewis RE. Posaconazole prophylaxis in hematologic cancer. N Engl J Med 2007 May 24;356(21):2214-5, author reply 5-8.
59. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36(11):1445-57
60. Morrison VA. Echinocandin antifungals: review and update. Expert Rev Antiinfect Ther 2006;4(2):325-42
61. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362(9390):1142-51
62. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
63. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16
64. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 2007;369(9572):1519-27
65. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
66. Intravenous Infusion (not for IV Bolus Injection) Cancidas (caspofungin acetate) for Injection package insert, February 2005 [cited 2007 November 16]; Available from: http://www.merck.com/product/usa/ pi_circulars/c/cancidas/cancidas_pi.pdf
67. Mycamine (micafungin sodium) for Injection package insert. August 2007 [cited 2007 November 16]; Available from: http://www.astellas.us/docs/ mycamine.pdf
68. Eraxis (anidulafungin) for Injection package insert. May 2007 [cited 2007 November 16]; Available from: http://media.pfizer.com/files/ products/uspi_eraxis.pdf
69. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39(11):1563-71
70. ClinicalTrials.gov. [cited 2007 November 16]; Available from: http://www.clinicaltrials.gov
71. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36(5):372-9
72. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53(5):337-49
73. Serrano Mdel C, Valverde-Conde A, Chavez MM, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003;45(2):131-5
74. Messer SA, Kirby JT, Sader HS, et al. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004;54(6):1051-6
75. Verweij PE, Oakley KL, Morrissey J, et al. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42(4):873-8
76. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety; and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;42(11):2898-905
77. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004;126(2):165-75
78. Steinbach WJ. Combination antifungal therapy for invasive aspergillosis - is it indicated? Med Mycol 2006;44:373-82
79. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003;37(Suppl 3):S188-224
80. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004;48(3):693-715
81. Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005;65(11):1461-80
82. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993;36(11-12):421-4
83. Maesaki S, Kohno S, Kaku M, et al. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother 1994;38(12):2843-5
84. Kontoyiannis DP, Lewis RE, Sagar N, et al. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000;44(10):2915-8
85. Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006;194(7):1008-18
86. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15(1):21-34
87. Najvar LK, Cacciapuoti A, Hernandez S, et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004;48(3):758-64
88. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39(6):797-802
89. Cesaro SS, Visintin GG. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2005;40(7): 1073-5, author reply 5
90. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004;39(6):803-5
91. Popp AI, White MH, Quadri T, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis 1999;3(3):157-60
92. Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005;103(11):2334-7
93. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98(2):292-9
94. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006;107(12):2888-97
95. Singh N, Limaye AR, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81(3):320-6
96. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000;31(4):859-68
97. Salerno CT, Ouyang DW, Pederson TS, et al. Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1998;65(5):1415-9
98. Pidhorecky I, Urschel J, Anderson T. Resection of invasive pulmonary aspergillosis in immunocompromised patients. Ann Surg Oncol 2000;7(4):312-7
99. Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 1998;158(3):885-90
100. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004;126(6):1783-8
101. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173(7):707-17
102. Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004;38(8):1131-6
103. Stevens DA. Th1/Th2 in aspergillosis. Med Mycol 2006;44(229-235)
104. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006;38(5):327-37
105. van Burik JA. Granulocyte transfusions as treatment or prophylaxis for fungal infections? Curr Opin Investig Drugs 2003;4(8):921-5
106. Feldmesser MM. Prospects of vaccines for invasive aspergillosis. Med Mycol 2005;43(7):571-87
107. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apher 1997;12(2):74-81
108. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004;101(12):2859-65
109. Dinser R, Grgic A, Kim YJ, Pfreundschuh M, Schubert J. Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft. Eur J Haematol 2005;74(5):438-41
110. Catalano L, Fontana R, Scarpato N, et al. Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica 1997;82(1):71-2
111. Verschraegen CF, van Besien KW, Dignani C, et al. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis 1997;29(4):436-8
112. Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005;84(11):734-41
113. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997;11(10):1621-30
114. Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999;106(3):689-96
115. Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981;304(20):1185-9
116. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187-205
117. Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2000;20(12):1432-40
118. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007;110(1):112-20
119. Sambatakou H, Denning DW. Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. Eur J Clin Microbiol Infect Dis 2005;24(9):628-33
120. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324(8):509-16
121. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991;163(4):908-11
122. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001;32(10):E137-9
123. Mamishi S, Zomorodian K, Saadat F, et al. A case of invasive aspergillosis in CGD patient successfully treated with amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005;4:4
124. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006;27(6):1307-10
125. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006;106(12):2664-71
126. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003;37(Suppl 3):S265-80
127. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005;43(Suppl 1):S207-38
128. Miller WT Jr, Sais GJ, Frank I, et al. Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. Chest 1994;105(1):37-44
129. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324(10):654-62
130. Kim SY, Lee KS, Han J, et al. Semiinvasive pulmonary aspergillosis: CT and pathologic findings in six patients. Am J Roentgenol 2000;174(3):795-8
131. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006;119(6):527, e17-24
132. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007;131(5):1435-41
133. Izumikawa K, Ohtsu Y, Kawabata M, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007;45(3):273-8
134. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52 (RR-10):142
135. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1-125, CE1-7
136. Cheng SM, Streifel AJ. Infection control considerations during construction activities: land excavation and demolition. Am J Infect Control 2001;29(5):321-8
137. Warris A, Verweij PE. Clinical implications of environmental sources for Aspergillus. Med Mycol 2005;43(Suppl 1):S59-65
138. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171 (6):1545-52
139. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326(13):845-51
140. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96(6):2055-61
141. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38(2):127-34
142. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138(9):705-13
143. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103(4):1527-33
144. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103(4):1557-9
145. Husain S, Zaldonis D, Kusne S, et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006;8(4):213-8
146. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005;24(12):2148-52
147. Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12(6):577-82
148. Tollemar J, Hockerstedt K, Ericzon BG, et al. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant Proc 1995;27(1):1195-8
149. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23(2):163-8
150. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97(2):450-6
151. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis, in lung-transplant recipients. Transplantation 2004;77(2):232-7
152. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93(11):3654-61
153. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006;27 (Suppl 1):36-44
154. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006;6(12):3008-16
155. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39(5):743-6
156. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39(7):425-9
157. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30(6):851-6
158. Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine (Baltimore) 1986;65(2):113-23
159. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004;89(2):207-14
160. Pagano L, Gleissner B, Fianchi L. Breakthrough zygomycosis and voriconazole. J Infect Dis 2005;192(8):1496-7, author reply 7
161. Tong SY, Peleg AY, Yoong J, et al. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007;9(3):241-3
162. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006;42(6):753-7
163. Girmenia C, Moleti ML, Micozzi A, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005;43(10):5395-6
164. Goodman D, Pamer E, Jakubowski A, et al. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002;35(3):E35-6
165. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007;45(4):321-46